17-20 June 2015 Lugano
![]() |
![]() |
![]() |
![]() |
7-OT | CHRONOS-1: Phase II trial of intravenous PI3K-&945;/-&946; inhibitor copanlisib in patients with relapsed/refractory indolent non-Hodgkins lymphoma | Martin Dreyling | ![]() |
![]() |
|||
8-OT | Design of a Phase 1/2, open-label, dose-escalation trial of the Toll-like receptor antagonist IMO-8400 in patients with MYD88 L265P-positive diffuse large B-cell lymphoma | James Baker | ![]() |
![]() |
|||
9-OT | Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial | Michael Wang | ![]() |
![]() |
|||
10-OT | Efficacy and Safety of Lenalidomide and Rituximab vs Placebo and Rituximab in a Phase 3 Trial in Relapsed/Refractory Non-Hodgkin Lymphoma | Rachel Sopko | ![]() |
![]() |
|||
11-OT | FIL-VERAL12: phase II randomized study with Rituximab-DHAP /- Bortezomib as induction in young relapsed/refractory Diffuse Large B-cell Lymphoma eligible to transplant. | ANNALISA CHIAPPELLA | ![]() |
![]() |
|||
13-OT | The Elderly Project by the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Eldelry Patients with Diffuse Large B-Cell Lymphoma. | Francesco Merli | ![]() |
![]() |
|||
14-OT | CLLR3 A randomized Phase II trial evaluating the chemotherapies FC/ B combined with GA101 followed by GA101 maintenance in relapsed/ refractory CLL | Nadine Kutsch | ![]() |
![]() |
|||
151-P | T-cell subpopulations quantified by flow cytometry in lymph node cell suspensions identify a group of patients with follicular lymphoma with favorable outcome | Laura Magnano Mayer | ![]() |
![]() |
|||
154-P | NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy | Alexander Deutsch | ![]() |
![]() |
|||
157-P | Prognostic impact of cell of origin profile in young patients with high risk diffuse large B cell lymphoma: results of the BIO-DLCL04 trial of Fondazione Italiana Linfomi | ANNALISA CHIAPPELLA | ![]() |
![]() |
|||
158-P | Cell of origin is not associated with survival after DLBCL relapse | Umar Farooq | ![]() |
![]() |
|||
159-P | Impact on survival of MYC genetic alterations but not MYD88L265P mutation in primary testicular DLBCL | Alexandra Valera | ![]() |
![]() |
|||
160-P | MYD88 L265P mutations, but not other variants, identify a subgroup of patients with ABC diffuse large B-cell lymphoma, extranodal involvement and poor outcome | JORDINA ROVIRA | ![]() |
![]() |
|||
161-P | MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma | Ting-Xun Lu | ![]() |
![]() |
|||
162-P | Analysis of double-hit lymphoma cases by genetic subtype | Daniel Landsburg | ![]() |
![]() |
|||
163-P | Molecular characterization of diffuse large B-cell lymphoma recurrences: clonal relationship and different modes of tumor evolution | Darius Juskevicius | ![]() |
![]() |
|||
164-P | Relapsed DLBCLs present frequent copy number variations of genes involved in lymphomagenesis with different pattern between early- and late-relapsed DLBCLs | BROSÉUS Julien | ![]() |
![]() |
|||
166-P | Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma | Kurt Bantilan | ![]() |
![]() |
|||
168-P | PRIMA-1Met induces myeloma and mantle cell lymphoma cell death, by impairing ROS/GSH balance. | Benoit Tessoulin | ![]() |
![]() |
|||
169-P | Chronic Lymphocytic Leukemia B-cells are rescued from apoptosis by extracellular vesicles from bone marrow mesenchymal stromal cells | Emerence Crompot | ![]() |
![]() |
|||
170-P | Prognostic significance of TET and IDH mRNA expression in chronic lymphocytic leukemia | Michal Van Damme | ![]() |
![]() |
|||
171-P | Optimal Treatment Strategies for Early-Stage Hodgkins Lymphoma with B Symptoms and Bulky Disease at Presentation | Jay Reddy | ![]() |
![]() |
|||
172-P | Infradiaphragmatic Hodgkin Lymphoma: long term outcome improved by chemotherapy-radiotherapy VS chemotherapy alone. | cédric rossi | ![]() |
![]() |
|||
173-P | Consolidation radiation after ABVD is effective treatment for ed patients with Hodgkins lymphoma (HL) with interim PET positive scans. | Noelle ORourke | ![]() |
![]() |
|||
174-P | Pencil Beam Scanning Proton Therapy for Lymphoma Patients with Mediastinal Involvement: A Dosimetric Study and Preliminary Clinical Data | Katerina Dedeckova | ![]() |
![]() |
|||
175-P | Cardiac Radiation Dose and Predicted Cardiac Mortality in the UK RAPID Trial in Early Stage Hodgkin Lymphoma | David Cutter | ![]() |
![]() |
|||
176-P | Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free time points and survival comparison to the general population in British Columbia. | Greg Hapgood | ![]() |
![]() |
|||
177-P | Healthcare utilization in the AETHERA trial: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post ASCT | vijayveer bonthapally | ![]() |
![]() |
|||
179-P | Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder (HL-PTLD): A Comparative Analysis of Prognosis and Survival | Andrew Evens | ![]() |
![]() |
|||
181-P | First in-patient proof of safety and efficacy of a 4th generation chimeric antigen receptor-modified T cells for the treatment of R/R CD30-positive lymphoma | Zhitao Ying | ![]() |
![]() |
|||
182-P | Chronic lymphocytic leukaemia treatment and outcome in the UKs population-based Haematological Malignancy Research Network | Russell Patmore | ![]() |
![]() |
|||
183-P | Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B-CLL cells and FCGR3A polymorphism. A study of FCGCLL/MW and GOELAMS groups. | Anne-laure Gagez | ![]() |
![]() |
|||
184-P | Results of a Phase II randomizing intensified rituximab pre-phase followed by standard FCR vs standard FCR in previously untreated patients with Active B-CLL. | Stephane Lepretre | ![]() |
![]() |
|||
185-P | A Randomised Study of F(C)R in Fit, Elderly Patients with Chronic Lymphocytic Leukaemia (CLL) shows high response rates and a dose intensity effect | Stephen Mulligan | ![]() |
![]() |
|||
186-P | Targeting Mutated BRAF with Vemurafenib is Safe and Highly Active in Relapsed/Refractory Hairy Cell Leukemia: a Phase-2 Italian Clinical Trial (HCL-PG01) | Enrico Tiacci | ![]() |
![]() |
|||
187-P | The clinical course of patients with follicular lymphoma in the rituximab era | inas el-najjar | ![]() |
![]() |
|||
188-P | Event-free Survival at 12 Months and Subsequent Overall Survival in Patients with Follicular Lymphoma Managed in the Rituximab Era | Emmanuel Bachy | ![]() |
![]() |
|||
189-P | Follicular lymphoma and clinical characteristics of histologic transformation | Miriam Mendez | ![]() |
![]() |
|||
190-P | RISK INCIDENCE OF FOLLICULAR LYMPHOMA TRANSFORMATION: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE SPANISH GELTAMO GROUP | Sara Alonso-Alvarez | ![]() |
![]() |
|||
191-P | Comparison of lenalidomide and rituximab with chemoimmunotherapy in patients with untreated grade 1-2 follicular lymphoma treated at the MD Anderson Cancer Center | Chan Yoon Cheah | ![]() |
![]() |
|||
192-P | Extended Dosing Lenalidomide with Intensified Rituximab in Untreated Indolent NHL | Nathan Fowler | ![]() |
![]() |
|||
196-P | Rituximab Maintenance (MR) improves PFS and OS in all Patients (pts) with Follicular Lymphoma (FL) - Individual Patient Data (IPD) meta-analysis | Liat Vidal-Fisher | ![]() |
![]() |
|||
199-P | Higher risk of rituximab intolerance in patients with Waldenstrm Macroglobulinemia | Jorge Castillo | ![]() |
![]() |
|||
201-P | Outcomes in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease patients treated with rituximab and liposomal doxorubicin (R-Dox) | Thomas Uldrick | ![]() |
![]() |
|||
202-P | Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP vs R-CHOP in the phase 3 LYM-3002 study | Gregor Verhoef | ![]() |
![]() |
|||
204-P | Clinical, metabolic and molecular responses with sequential R-CHOP, high-dose cytarabine, and iodine-131 tositumomab-based transplant in Mantle Cell Lymphoma | Kurt Bantilan | ![]() |
![]() |
|||
205-P | Multi-center phase II study with lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: survival update and health-related quality-of-life analysis | Jia Ruan | ![]() |
![]() |
|||
207-P | Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma | Peter Martin | ![]() |
![]() |
|||
209-P | High Dose Sequential Chemotherapy with Rituximab and ASCT as First Line Therapy in Adult MCL Patients: Clinical and Molecular Response of the MCL0208 Trial, a FIL Study. | Sergio Cortelazzo | ![]() |
![]() |
|||
210-P | The standard, revised and a simplified International Prognostic Index reliably predict outcome in patients with PET/CT-staged DLBCL treated with R-CHOP | Diego Villa | ![]() |
![]() |
|||
211-P | Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of CNS relapse with R-CHOP(-like) therapy | Tarec Christoffer El-Galaly | ![]() |
![]() |
|||
212-P | Evaluation of the site of central nervous system (CNS) relapse in patients with Diffuse Large B-cell lymphoma (DLBCL) by the CNS risk model | Roopesh Kansara | ![]() |
![]() |
|||
213-P | Clinical and Treatment-Related Features Determining the Risk of Late Relapse in Patients with Diffuse Large B-cell Lymphoma | Lena Modvig | ![]() |
![]() |
|||
215-P | Spleen involvement identified on baseline PET imaging influences outcome of young patients with high risk diffuse large B cell lymphoma treated with R-CHOP14 but not R-ACVBP | Olivier Casasnovas | ![]() |
![]() |
|||
217-P | Vincristine omission, but not dose reduction, is associated with decreased survival in elderly DLBCL patients | Salma Afifi | ![]() |
![]() |
|||
218-P | Outcome analysis of diffuse large B cell lymphoma (DLBCL) in HIV-infected and immunocompetent (IC) patients: The Swiss HIV Cohort study (SHCS) | Annarita Conconi | ![]() |
![]() |
|||
219-P | Secondary CNS lymphoma in the rituximab-era: Data on the first 100 patients from a prospective registry | Stephan Kreher | ![]() |
![]() |
|||
220-P | Dose-Dense Chemoimmunotherapy and Early CNS Prophylaxis for High-Risk DLBCL Interim Results from a Nordic Phase II Study | Sirpa Lepp | ![]() |
![]() |
|||
221-P | Systemic high-dose methotrexate (HD-MTX) consolidation in poor-risk diffuse large B-cell lymphoma is associated with improved survival in Germinal Centre B-cell phenotype | Michael Gilbertson | ![]() |
![]() |
|||
222-P | The addition of Rituximab to CODOX-M & IVAC in first Line therapy of poor risk Burkitt Lymphoma (IPI 3-5) yields an excellent outcome: a Phase 2 UK NCRI/LLR Trial (LLR 04058) | andrew mcmillan | ![]() |
![]() |
|||
225-P | Prognostic impact of immunohistological profiling in primary CNS lymphoma | Stephan Kreher | ![]() |
![]() |
|||
226-P | Addition of Rituximab to the Treatment of Newly Diagnosed Primary CNS Lymphoma is Associated with Improved Outcome: A French LOC Network study | Emmanuel GYAN | ![]() |
![]() |
|||
227-P | BAM induction followed by autologous stem cell transplantation for patients with primary central nervous system lymphoma: a multicenter study from the Spanish group GEL-TAMO | MIRIAM LÓPEZ-PARRA | ![]() |
![]() |
|||
228-P | High efficiency and tolerance of Temozolomide in relapse/refractory primary vitreo-retineal lymphoma: a multicentric study from the LOC network | Sylvain Choquet | ![]() |
![]() |
|||
229-P | Temsirolimus for primary CNS lymphoma | Stephan Kreher | ![]() |
![]() |
|||
230-P | Long-Term Outcome of 490 Patients with Early-Stage Extra-nodal Marginal Zone Lymphoma | Sewit Teckie | ![]() |
![]() |
|||
231-P | Clinical Characteristics and Patterns of Care of Patients (pts) with Peripheral T-cell Lymphoma (PTCLs) according to age at time of diagnosis: A T-Cell Project snapshot. | Monica Bellei | ![]() |
![]() |
|||
232-P | Characteristics and Patterns of Care of Patients (pts) =70 years with T-cell non-Hodgkin Lymphoma (TCL) in the United States (US) | Chadi Nabhan | ![]() |
![]() |
|||
233-P | A large prospective multicenter study of peripheral T-cell lymphoma in Thailand: clinical, histopathology, treatment outcomes, and survival | Jakrawadee Julamanee | ![]() |
![]() |
|||
234-P | A proposal of a new staging systemfor extranodal natural killer T-cell lymphoma, nasal-type: a multicenter study from Chinese Southwest Oncology Group (CSWOG) and Asia Lymphoma Study Group (ALSG) | Tongyu Lin | ![]() |
![]() |
|||
235-P | A clinicopathological study of Lennert lymphoma and possible prognostic factors | Daisuke Kurita | ![]() |
![]() |
|||
236-P | SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA IN THAILAND: CLINICAL OUTCOMES, TREATMENTS, AND PROGNOSTIC FACTORS | Udomsak Bunworasate | ![]() |
![]() |
|||
237-P | Immunophenotypic heterogeneity of T-LGLL: clinical and biological implications | Renato Zambello | ![]() |
![]() |
|||
238-P | Breast Implant Associated Anaplastic Large cell Lymphoma: a new distinct clinicopathologic entity. | Camille Laurent | ![]() |
![]() |
|||
239-P | Molecular Heterogeneity of ALK-negative Anaplastic Large Cell Lymphoma | Andrew Feldman | ![]() |
![]() |
|||
243-P | Polyethylene glycol conjugated asparaginase-CHOP in adult newly diagnosed extranodal NK/T-cell lymphoma: a multi-center prospective phase II study | Wen Zheng | ![]() |
![]() |
|||
244-P | Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population | Shunan Qi | ![]() |
![]() |
|||
245-P | Clinical Outcome of P-Gemox for Newly Diagnosed Stage III/IV or Relapsed/Refractory ENKTL | HuiQiang Huang | ![]() |
![]() |
|||
247-P | The role of transplant in the treatment of Peripheral T-cell Lymphomas (PTCLs): an analysis from the T-Cell project database. | Monica Bellei | ![]() |
![]() |
|||
248-P | Phase II study of SMILE chemotherapy for relapsed/refractory peripheral T-cell lymphoma | Ritsuro Suzuki | ![]() |
![]() |
|||
249-P | Bendamustine treatment in refractory/relapsed T cell lymphomas: a retrospective multicenter study | Emilie Reboursiere | ![]() |
![]() |
|||
250-P | The mTORC1 Inhibitor Everolimus Produces Tumor Responses in Patients with Relapsed T-cell Non-Hodgkin Lymphoma | Thomas Witzig | ![]() |
![]() |
|||
252-P | Baseline metabolic tumor burden in DLBCL affects response to immuno-chemotherapy and patients outcome through influence of rituximab pharmacokinetics. A LYSA group study. | Olivier Casasnovas | ![]() |
![]() |
|||
254-P | Role of bone marrow biopsy (BMB) in classic Hodgkin Lymphoma (cHL) staging in FDG-PET/CT era. | benedetta puccini | ![]() |
![]() |
|||
255-P | Hodgkin Lymphoma: PET-CT or bone marrow biopsy? | Zeinab Abou Yehia | ![]() |
![]() |
|||
257-P | PROGNOSTIC VALUE OF INTERIM FDG-PET/CT IN 100 DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP ACCORDING TO INTERPRETATION CRITERIA AND PRETHERAPEUTIC PROGNOSTIC FACTORS | Caroline Faes | ![]() |
![]() |
|||
258-P | Blinded evaluation of the prognostic value of FDG-PET/CT after 2 cycles of RCHOP in DLBCL UK-NCRI study | Mikhaeel George | ![]() |
![]() |
|||
259-P | No survival benefit associated with routine imaging for classical Hodgkin lymphoma in complete remission: A Danish-Swedish population-based study | Tarec Christoffer El-Galaly | ![]() |
![]() |
|||
261-P | Biological Rational for Sequential Targeting of Bruton Tyrosine Kinase and Bcl2 to Overcome Cd40-induced BH3-mimetics Resistance in Mantle Cell Lymphoma | David Chiron | ![]() |
![]() |
|||
264-P | Preclinical evaluation of the novel pleiotropic BCR kinase inhibitor IQS019 in in vitro and in vivo models of B lymphoid neoplasms | Gael Roue | ![]() |
![]() |
|||
266-P | Transcriptomic profiling of response to PI3K inhibition by BKM120 in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) | Micheal Coyle | ![]() |
![]() |
|||
267-P | Differential expression of PI3K isoforms/PTEN in follicular lymphoma and diffuse large B-cell lymphoma - therapeutic implications | Lim Soon Thye | ![]() |
![]() |
|||
268-P | Inhibition of both PI3Ka and PI3Kd by Copanlisib is essential to attenuate both BCR-dependent and BCR-independent activation of NF&954;B and proliferation in DLBCL cells | Juliane Paul | ![]() |
![]() |
|||
269-P | Pre-clinical lymphoma models show high sensitivity to the small molecule YK-4-279 | Elaine Chung | ![]() |
![]() |
|||
271-P | The BET bromodomain inhibitor OTX015 (MK-8628) affects the expression of microRNAs involved in the pathogenesis of lymphoma: in vitro and in vivo evidence | Afua Adjeiwaa Mensah | ![]() |
![]() |
|||
272-P | OTX015 (MK-8628) targets genes with high levels of promoter H3K4me3 involved in key signalling pathways in splenic marginal zone lymphoma and mantle cell lymphoma | Chiara Tarantelli | ![]() |
![]() |
|||
273-P | Pixantrone has pre-clinical synergistic activity when combined with targeted agents in diffuse large B-cell lymphoma. | Chiara Tarantelli | ![]() |
![]() |
|||
274-P | Novel CD37-Targeting Antibody-Drug Conjugate (ADC), IMGN529, Has Synergistic Activity in Combination with Rituximab in Non-Hodgkin Lymphoma (NHL) Models | Angela Romanelli | ![]() |
![]() |
|||
275-P | A variant of obinutuzumab with abolished ADCC, ADCP and CDC is as efficient as rituximab in B cell depletion and antitumor activity | Christian Klein | ![]() |
![]() |
|||
277-P | Targeting the MUC1-C oncoprotein is associated with downregulation of TIGAR and ROS-mediated cutaneous T-cell lymphoma cell death | Salvia Jain | ![]() |
![]() |
|||
278-P | MYC and CHK1 Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models With Anti-Proteasomal Therapy | Andrew Evens | ![]() |
![]() |
|||
279-P | Alisertib Exhibits Broad Activity And Selectively Synergizes With Romidepsin In Preclinical Models Of T-Cell Lymphoma | Kelly Zullo | ![]() |
![]() |
|||
280-P | Interim Analysis of a Phase 1b Study Evaluating the Safety of GS-9820, a Second-Generation PI3Kd-Inhibitor, in Relapsed/Refractory Lymphoid Malignancies | Arnon Kater | ![]() |
![]() |
|||
282-P | Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 Alliance) | Patrick Johnston | ![]() |
![]() |
|||
283-P | Safety and clinical activity of Temsirolimus in combination with Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma | Mathias Witzens-Harig | ![]() |
![]() |
|||
286-P | Phase I dose-escalation study of BI 836826 in patients (pts) with relapsed or refractory non-Hodgkin lymphoma (NHL) of B cell origin | Janet Lightwood | ![]() |
![]() |
17-20 June 2015 Lugano
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|